Adaptive Biotechnologies and Genentech said they have entered into a worldwide collaboration and license agreement to develop, manufacture and commercialize novel neoantigen directed T-cell therapies for the treatment of a broad range of cancers.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
